FDA Wants Easier Approvals for 3D Breast Cancer Scanners
Published Date: 8/10/2026
Proposed Rule
Summary
The FDA wants to change how digital breast tomosynthesis (DBT) systems are classified, moving them from a strict, high-level category (Class III) to a more flexible one (Class II) with special safety rules. This affects companies making these breast imaging devices, making it easier and faster to get them approved. Comments on this change are open until October 9, 2026, so stakeholders should act fast to share their thoughts!
Analyzed Economic Effects
6 provisions identified: 4 benefits, 2 costs, 0 mixed.
FDA Identifies Ten Health Risks From DBT
FDA lists probable health risks tied to DBT systems, including corrupted or non-diagnostic images; incorrect image interpretation; inadequate breast coverage; inappropriate compression; device failure or malfunction; user error; excessive x-ray exposure; interference with other devices; adverse tissue reaction; and infection. These risks could lead to delayed or incorrect diagnosis, extra radiation exposure, unnecessary procedures, or patient injury.
DBT Devices Shift From PMA to 510(k)
FDA proposes to reclassify digital breast tomosynthesis (DBT) systems from class III (which require a Premarket Approval or PMA) to class II, meaning manufacturers would submit a premarket notification (a 510(k)) instead of a PMA before marketing. FDA says a 510(k) is generally less burdensome and may shorten review timelines, which could lower the regulatory cost and speed market entry for device makers.
You May See More DBT Availability
FDA says reclassifying DBT systems to class II could enable more manufacturers to develop these devices and provide more timely patient access to DBT for breast cancer screening and diagnosis. If finalized, FDA expects increased device availability and patient access as a result of the less burdensome 510(k) pathway.
DBT Facilities Must Follow MQSA Rules
FDA states that DBT is a mammographic modality under the Mammography Quality Standards Act (MQSA), so facilities that perform mammography using DBT systems are subject to MQSA requirements. That means facilities using DBT must meet MQSA standards and QC requirements when they offer these exams.
Postmarket Data Shows Limited Serious Safety Signals
As of July 21, 2026, FDA report searches found 968 Medical Device Reports for DBT systems, about 1 percent reported serious injury (not necessarily device-caused), five Class II recalls, and no Class I or Class III recalls. FDA says most MDRs indicated no patient impact and that the postmarket data support special controls rather than PMA-level oversight.
Manufacturers May Use Predetermined Change Plans
FDA notes that manufacturers may use Predetermined Change Control Plans (PCCPs) approved or cleared by FDA to implement future device modifications without submitting a new 510(k) or PMA supplement for each change, under section 515C of the FD&C Act. Using PCCPs can reduce the need for separate submissions when changes fall within the approved plan.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19563, Improving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Information
The government wants your ideas on how to make it easier and safer for people with Type 1 diabetes to get special cells from deceased donors that help manage their disease. They’re thinking about new rules to treat these cells like organs, which could improve how they’re shared and used. If you have thoughts, send them by November 9, 2026—this could change how patients get life-changing treatments and how doctors handle them.
2026-19419, Sanjay Kumar: Final Debarment Order
Sanjay Kumar is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime involving fake goods. He didn’t respond to the FDA’s notice, so the ban starts on September 23, 2026. He can apply to end the ban anytime, but must follow special rules to keep info private.
Previous / Next Documents
Previous: 2026-16197, Protecting Against National Security Threats to the Communications Supply Chain Through the Equipment Authorization Program
The Federal Communications Commission (Commission or FCC) issues a Third Further Notice of Proposed Rulemaking seeking comment on a broad set of additional measures to strengthen the security and integrity of its equipment authorization program. The measures include bifurcating the Covered List into producer/provider-based and production location-based categories; addressing "white labeling" of covered equipment; hardware and software bill of materials (HBOM/SBOM) disclosure requirements; further prohibitions or presumptions against authorizing equipment containing Covered List components or software; certification requirements for devices in Covered List sectors; reforms to equipment importation, marketing, and pre-authorization operation rules; restrictions on use of the FCC logo; streamlined revocation procedures; codification of permissive-change waivers for software, firmware, and hardware updates to covered equipment; codified definitions for UAS, UAS critical components, and routers; term limits on equipment authorizations; registration of Supplier's Declaration of Conformity (SDoC) devices; modernization of the Commission's equipment authorization database; updates to submarine cable Covered List rules; and a proposal to require a U.S.-based liable party for FCC-certified equipment.
Next: 2026-16228, HUD's Implementation of the Fair Housing Act's Disparate Impact Standard; Amendments to HUD's Title VI Regulations
HUD published a notice of proposed rulemaking in January of 2026 that proposed to remove HUD's disparate-impact regulations and leave interpretation of disparate-impact liability under the Fair Housing Act to the courts. This supplemental notice of proposed rulemaking continues HUD's efforts to remove or revise regulations that prohibit conduct having a disparate impact without evidence of discriminatory intent. Through this rule, HUD is proposing to remove provisions in HUD's Title VI implementing regulations that impose disparate-impact liability on recipients of HUD Federal financial assistance. If finalized, this rule would improve consistency within HUD's own regulations and between HUD's regulations and the Title VI regulations recently revised by the Department of Justice (DOJ). This rule reopens the public comment period of HUD's January 2026 proposed rule on disparate-impact liability; HUD will only consider comments on topics related to this supplemental notice of proposed rulemaking during the reopened comment period.